Our goal is to have HPV vaccination as part of State mission: MSD India MD

In a Q&A, Rehan A Khan talks about his firm's strong focus on R&D and its commitment to making drugs affordable

Rehan A Khan

Rehan A Khan

Sohini Das Mumbai
MSD India has signed several agreements around molnupiravir during the pandemic, and says that going forward, its focus for the Indian market would be vaccines and oncology. In an interview with Sohini Das, Rehan A Khan, Managing Director, MSD India Region speaks about how the firm expects HPV vaccination to become a part of the national immunisation mission. Edited excerpts:

How has business fared during the past two years of the pandemic?  

The year 2021 was a defining one in India's healthcare landscape. As one of the five fastest growing MNCs in India, we had successfully announced non-exclusive voluntary licensing agreements for the drug molnupiravir (an investigational oral antiviral medicine that significantly reduces the risk of hospitalisation or death) with

First Published: Jun 20 2022 | 4:02 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com